Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatment.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Ping Gong, Yunlei Hou, Changliang Hu, Qi Huang, Shuang Li, Zhiwei Li, Jiuyu Liu, Yajing Liu, Ruifeng Miao, Le Ren, Minghui Tong, Zhiguo Xi, Long Zhang, Na Zhang, Yanfang Zhao

Ngôn ngữ: eng

Ký hiệu phân loại: 784.190288 General principles, musical forms, instruments

Thông tin xuất bản: France : European journal of medicinal chemistry , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 695271

Polo like kinase 1 (PLK1) is a serine/threonine kinase that plays an important role in multiple phases of the cell cycle, inhibiting its activity has been considered an effective treatment for acute myeloid leukemia (AML). Here, we reported a series of highly potent PLK1 inhibitors. Among them, compound WD6 was identified as the most promising PLK1 inhibitor, with an IC
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH